Home » ETF » GNOM

GNOM - Global X Genomics & Biotechnology ETF

Stock Price: $22.36 USD 0.60 (2.76%)
Updated Apr 21, 2021 4:00 PM EDT - Market closed
Assets $205.68M
NAV $21.76
Expense Ratio 0.50%
PE Ratio -460.63
Beta (5Y) 1.10
Dividend (ttm) $0.03
Dividend Yield 0.15%
Ex-Dividend Date Dec 30, 2020
1-Year Return -
Trading Day April 21
Last Price $22.36
Previous Close $21.76
Change ($) 0.60
Change (%) 2.76%
Day's Open 21.77
Day's Range 21.60 - 22.36
Day's Volume 86,499
52-Week Range 13.84 - 28.45

Fund Description

The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index (underlying index). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.

Asset Class
Inception Date
Apr 5, 2019
Ticker Symbol
Index Tracked
Solactive Genomics Index

Top 10 Holdings

43.10% of assets
Pacific Biosciences of CaliforniaPACB5.43%
Agilent TechnologiesA4.45%
CRISPR TherapeuticsCRSP4.39%
Arrowhead PharmaceuticalsARWR3.91%
Intellia TherapeuticsNTLA3.81%
Ultragenyx PharmaceuticalRARE3.77%
Alnylam PharmaceuticalsALNY3.72%
View More Holdings


Ex-DividendAmountPay Date
Dec 30, 2020$0.032Jan 8, 2021
Full Dividend History


Hide News
  • All
  • Videos
  • Conversation

Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.

3 months ago - ETF Trends

The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.

Other tickers mentioned: ARKG, BTEC, IDNA, XBI
3 months ago - Zacks Investment Research

It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over 6...

3 months ago - ETF Trends

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.

Other tickers mentioned: CNBS, IHE, IHF, IHI, PJP, XHE
5 months ago - Zacks Investment Research

Genomics ETFs have surged of late; here's why

Other tickers mentioned: ARKG, IDNA
6 months ago - Zacks Investment Research

Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.

Other tickers mentioned: AMZA, TAN, THCX, XSD
6 months ago - Zacks Investment Research

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Other tickers mentioned: ARKG, IDNA, PBE
6 months ago - Zacks Investment Research

The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.

Other tickers mentioned: BETZ, EDOC, ICLN, IEZ
7 months ago - Zacks Investment Research

Jay Jacobs: These High-Growth ETF Themes Have Seen Triple-Digit Returns In Coronavirus Rally

YouTube video

Jay Jacobs, SVP and head of research and strategy at Global X ETFs, joined the podcast this week to discuss thematic investing and the new Global X Telehealth ETF (EDOC). Plus, we take a look at two ETF...

Other tickers mentioned: SNSR
7 months ago - Investors Business Daily

Disruptive technology is always an interesting play for investors to consider and the genomics market is one to watch closely. According to the “Genomics Market – Growth, Trends, and Forecasts (2020-202...

Other tickers mentioned: ARKG, GDNA
8 months ago - ETF Trends

Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.

Other tickers mentioned: CLOU, HERO, RYT, VGT, XLK
8 months ago - CNBC

Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX, potentially bolstering the genetic inform...

Other tickers mentioned: ARKG, XBI
9 months ago - ETF Trends

In the scramble to develop a Coronavirus vaccine, genomics investments are receiving renewed attention and rewarding investors in the process. Those sentiments are applicable to the Global X Genomics & ...

10 months ago - ETF Trends

Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.

Other tickers mentioned: IEZ, KBWD, SDIV, SILJ
10 months ago - Zacks Investment Research

The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are deliver...

Other tickers mentioned: ARKG
10 months ago - Benzinga

The ETF GNOM hit a 52-week high on May 22. Can it rally further?

10 months ago - Zacks Investment Research

Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.

Other tickers mentioned: ARKG, IDNA, PBE
10 months ago - Zacks Investment Research

Declining costs are viewed as one of the biggest factors driving the genomics and data suggest those costs continue falling, a scenario that could benefit ETFs, such as the Global X Genomics & Biotechno...

1 year ago - ETF Trends

Due in large part to the J.P. Morgan Health Care conference in San Francisco, the biotechnology industry’s marquee yearly confab, January is often a strong month for related equities and ETFs.

1 year ago - ETF Trends

While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.

Other tickers mentioned: BBC, IEZ, PXJ, SBIO, SIL, SILJ, SMH ...
1 year ago - Zacks Investment Research

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Other tickers mentioned: BBC, CNCR, IBB, SBIO, XBI
1 year ago - Zacks Investment Research

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other tickers mentioned: MGTX, NTLA, PIRS, QURE, VRTX
1 year ago - Zacks Investment Research

The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

Other tickers mentioned: ARKG, PBE
1 year ago - Zacks Investment Research

Healthcare bounced back with an outperformance starting the fourth quarter.

Other tickers mentioned: BBC, CNCR, IHF, IRWD, JNCE, OSMT, SBIO ...
1 year ago - Zacks Investment Research

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Other tickers mentioned: BBC, IHF, SBIO, XBI, XPH
1 year ago - Zacks Investment Research

When it comes to growth stocks, investors often expect they will pay up to access that.

1 year ago - Benzinga

The Global X Genomics & Biotechnology ETF (Nasdaq: GNOM) debuted earlier this year, making it one of the newest additions to the biotech ETFs fray, but despite its rookie status, GNOM is a fund with amp...

1 year ago - ETF Trends